ImmunityBio, Inc. (IBRX) Stock

ImmunityBio, Inc. is a clinical-stage biotechnology company at the forefront of developing innovative therapies and vaccines that harness the power of the immune system to combat cancers and infectious diseases. The company's comprehensive approach includes advanced immunotherapy and cell therapy platforms, featuring antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems.

ImmunityBio is actively advancing a pipeline of therapeutic agents through Phase II and III clinical trials aimed at treating both liquid and solid tumors, such as bladder, pancreatic, and lung cancers. Additionally, the company is focused on addressing significant pathogens including SARS-CoV-2 and HIV, highlighting its commitment to tackling urgent global health challenges.

The company's collaborative efforts are extensive, with strategic partnerships including the National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc. ImmunityBio also maintains license agreements with key entities such as CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and others, underscoring its dedication to leveraging synergistic innovations in biotechnology.

Founded in 2014 and headquartered in San Diego, California, ImmunityBio continues to drive forward groundbreaking research and development initiatives aimed at transforming the landscape of cancer treatment and infectious disease prevention through its pioneering immunotherapy platforms and strategic partnerships.